Lv1
70 积分 2021-06-28 加入
Clinically relevant end points and new drug approvals for myeloma
15天前
已完结
Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database
15天前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
5个月前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
5个月前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
5个月前
已完结
BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects
5个月前
已完结
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
5个月前
已完结
Multiple myeloma
5个月前
已完结
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
6个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
6个月前
已完结
皖公网安备34019202002308
